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The success of prevention of mother-to-child transmission (PMTCT) programmes (Options A and B) in middle-income 
countries, together with clinical trial data on antiretroviral (ARV) treatment as prophylaxis, has emboldened UN agencies to 
aggressively promote lifelong ARVs for PMTCT (Option B+). Unsubstantiated claims submit that Option B+ is cost-effective at 
population-level, will protect HIV-negative male partners, improve maternal and infant health, and increase ARV coverage. We 
provide counterfactual arguments about the ethics, medical safety, programme feasibility and economic benefits of Option B+.
Option B+ offers no advantage to PMTCT and there are social hazards associated with privileging pregnant woman for treatment 
over men and non-pregnant women, especially with the absence of data to suggest that discordant relationships are more frequent 
among pregnant women or that they contribute disproportionately to the horizontal HIV transmission. The benefits and safety of 
long-term ARVs – including adherence and resistance – in mothers who do not need treatment for their own health, need to be 
considered, as well as, crucially, health service costs. The assumption that a decrease in efficiency caused by inappropriate targeting 
is compensated for by lower recruitment costs, is untested. Lives could be saved instead with appropriately targeted interventions. 
Countries should make individual decisions based on their HIV epidemiology, resources, priorities and local evidence.
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Advocacy of the extreme antiretroviral therapy (ART) 
Option B+ for pregnant women by some organisations and 
international agencies,[1,2] particularly at the AIDS 2012 
conference in Washington DC, USA,[3] with little consultation, 
debate and discussion, is worrying. 
Supporters of Option B+ argue that it is superior, owing to 
additional ART coverage (because CD4 cell count results are 
not needed), additional maternal health benefits, and protection 
of discordant male partners. However, these benefits have not 
been validated due to the fast pace and single-mindedness 
of advocacy. The business case,[2] which supports the use of 
Option B+ in resource-limited settings, does not fully address 
four critical considerations: ethics, medical safety and benefits, 
programme feasibility, and economic concerns (Table 1).
Options A, B and B+ have similar protective benefits with 
respect to the prevention of mother-to-child transmission 
(PMTCT) of HIV.[4,5] Data suggest that triple ART may provide 
maternal health benefits even up to CD4 cell counts of 600 
cells/μl,[5,6] and that it reduces HIV transmission between 
discordant couples.[7] 
However, these data alone do not justify favouring pregnant 
woman for treatment over men and non-pregnant women. If 
Option B+ is used because it may decrease mortality and disease 
progression in HIV-infected mothers with CD4 counts >350 
cells/μl, then the justification should extend to the families, 
partners, friends and community of the pregnant women, and 
the whole HIV-infected population. The application of different 
treatment thresholds in sub-populations could create tensions 





between people with and those without access to treatment. If Option 
B+ is a phase-in of a universal test-and-treat goal, then this should be 
made explicit, and the ethics of early treatment initiation in the context 
of unmet need warrant discussion. Option B+ is being considered only 
in resource-limited settings with a high HIV burden, to target pregnant 
women for non-pregnancy-related interventions such as treatment-as-
prevention and early treatment initiation. There are no data to suggest 
that pregnant women have above-average involvement in discordant 
relationships or that pregnant women contribute disproportionately to 
the horizontal transmission of HIV. 
The medical benefits and safety of long-term antiretrovirals (ARVs) 
need to be considered, including adherence and resistance, in sub-
populations of mothers and infants who do not need treatment for 
their own health. For example, increased exposure to ART, as will be 
experienced with Options B or B+, may increase adverse pregnancy 
outcomes such as pre-term delivery and low birth weight.[8] In resource-
limited settings this may increase risk for infant death. Increased exposure 
to tenofovir may also increase potential for renal toxicity in mothers[9] 
and poor growth outcomes in infants.[10] Additionally, Option B+ is costly, 
owing to the need for additional drugs, laboratory tests, human resources 
Table 1. Summary of PMTCT options and concerns with Option B+
PMTCT options
Option A
Mother • CD4 count ≤350 cells/μl: triple ARVs starting as soon as diagnosed; continued for life 
• CD4 count >350 cells/μl: 
• Antepartum: AZT from 14 weeks’ gestation
• Intrapartum: single-dose (sd) NVP and AZT + 3TC
• Postpartum: AZT + 3TC for 7 days.
 Infant • Daily sd NVP for 6 weeks in non-BF infants or mother receiving ART or until 1 week after all BF has stopped.
Option B
Mother • All pregnant women will be started on triple ARVs regardless of CD4 cell count. 
• CD4 count ≤350 cells/μl: triple ARVs will be continued for life
• CD4 count >350 cells/μl: triple ARVs will be started as early as 14 weeks’ gestation, continued intrapartum and 
through childbirth and stopped if not breastfeeding or continued until 1 week after cessation of all breastfeeding.
Infant • Daily NVP or AZT from birth to 4 - 6 weeks of age.
Option B+
Mother • All pregnant women will be started on triple ARVs regardless of CD4 cell count and this will be continued for life.
Infant • Daily NVP or AZT from birth to 4 - 6 weeks of age.
Concerns with Option B+
Ethical • Should pregnant women be prioritised for treatment for reasons other than the immediacy of their medical condition?
• Have the implications of introduction or exacerbation of intra-household and community tensions because of different 
treatment access been adequately considered?
• Should selective test-and-treat interventions be considered ahead of achieving universal access for patients with CD4 
counts <350 cells/μl?
• Is it ethical to give women with high CD4 cell counts treatment for life without fully understanding the long-terms 
benefits and risks? 
• Will the rollout of ARVs for a selected group within the population compromise the provision of ARVs for other 
groups who need it for their own health in resource-limited settings or settings with drug-supply restrictions?
Medical • Are there benefits for mother-to-child transmission and long-term infant HIV-free survival?
• Are the benefits for maternal health worth the potential increase in drug resistance?
• Will long-term exposure to ARVs in mothers reduce horizontal transmission and change the trajectory of the HIV epidemic? 
• Do we have enough evidence to suggest that pregnant women and new mothers are a risk group who have discordant 
relationships and contribute to the HIV epidemic?
Programmatic • Can B+ be implemented in strained health systems without disruption of the introduction of treatment programmes? 
• Will the implementation of B+ need scarce resources such as personnel, laboratory support and drugs to be diverted 
from the drive towards universal access to HIV treatment or universal access to treatment for other non-HIV life-
threatening conditions or infectious diseases? 
• Will the necessary levels of adherence be maintained?
Economic • Is the assumption valid that economies of scope will favour this 3-in-1 intervention (i.e. PMTCT, treatment and 
treatment-as-prevention)?
• If retention rates are not high, will the economic argument in favour of B+ be invalid?





and other health-system expenditures. Furthermore, experience of 
Option B+ is restricted to Malawi and Rwanda; this is insufficient to 
measure universal feasibility. The success of Option B+ depends on the 
retention of women in treatment programmes, which increases pressure 
on already strained health systems.[11,12] Recent data show that adequate 
adherence drops from 75.7% (95% CI: 71.5 - 79.7%) during pregnancy to 
53% (95% CI 32.8 - 72.7) postpartum among women who meet present 
ART criteria.[13] The public health implications (including resistance and 
potential for future treatment) of reduced adherence in Options B and 
especially B+ are unknown and likely to be concerning. Finally, although 
higher treatment thresholds may be necessary, particularly in regions 
with high fertility rates, it is unclear whether universal provision of ART 
for pregnant women only is appropriate. 
The business case for Option B+ assumes that economies of scope are 
generated by implementation of the triple combination of PMTCT of 
HIV, treatment and treatment-as-prevention. If each intervention were 
to be introduced separately, except for PMTCT, then the targeting of 
pregnant women only would not be appropriate. The recommendation 
of Option B+ is based on the untested assumption that the decrease 
in efficiency caused by inappropriate targeting is compensated for 
by lower recruitment costs. Similar to the economic analysis of Test-
and-Treat,[14] small changes to assumptions, particularly relating to 
retention, have large implications. Indeed, if the scope assumptions are 
incorrect, Option B+ will cost lives, which could have been saved with 
appropriately targeted treatment and treatment-as-prevention.
Advocacy is critical, and reliance only on what has been scientifically 
proven would result in slow progress. However, with so many 
unknowns, the strong push for countries to switch to Option B+ is 
premature. A switch now would be dangerous, ignoring severe ethical, 
safety, feasibility and economic concerns. Countries should make 
their own decisions based on their local situation, resources, priorities 
and evidence. International agencies should guide, but not pressure, 
ministries into making decisions, particularly where evidence is weak. 
A clear decision-making process is essential.
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